Skip to content


  • Letter
  • Open Access

Concomitant assessment of PSP and NT-proCNP as predictive markers of sepsis in severe trauma patients under mechanical ventilation

  • 1, 2Email author,
  • 3,
  • 3,
  • 4,
  • 2, 5,
  • 3,
  • 2, 5,
  • 1 and
  • 1, 2
Critical Care201317:434

  • Published:


  • Trauma Patient
  • Injury Severity Score
  • Validation Cohort
  • Aspiration Pneumonia
  • Severe Trauma

In intensive care units (ICUs), a great deal of research is devoted to finding new biomarkers to help physicians in the prediction of outcome. The pancreatic stone protein/regenerating protein (PSP) [1, 2] and the amino terminal pro-C-type-natriuretic-peptide (NT-proCNP) [3] were assessed as markers of sepsis in patients with moderate trauma and as prognostic markers of mortality for PSP [4]. The objective of this study was to analyze separately the roles of these two biomarkers in the prediction of sepsis in patients with severe trauma.

This retrospective observational study was conducted over the course of 24 months in a trauma ICU at a university hospital. Trauma patients who were under mechanical ventilation, had an Injury Severity Score of at least 25, and were at least 18 years old were included. Clinical exclusion criteria were aspiration pneumonia or gut perforation during trauma, immunosuppressive therapy, and death in the first 48 hours. Our institutional ethics committee ('Comité de Protection des Personnes') waived the need for signed consent as samples were obtained on residual blood after routine follow-up. They recommended delivering oral information about the study to the patient or their family.

Blood samples were collected at 8 a.m. on the first two days after injury. Every patient who had a frozen plasma sample available was retrospectively included. Plasma levels of PSP and NT-proCNP were measured by using the enzyme-linked immunosorbent assay (ELISA) technique.

Sixty-one patients were included, and 36% developed pneumonia (median delay of 4 days). At days 1 to 2, neither PSP nor NT-proCNP concentrations were significantly different between sepsis and non-sepsis groups (Figure 1), even after stratification of clinical data (transfusion, neurological trauma). The area under the receiver operating characteristic curve (AUC) was not significantly different from 0.5 for PSP and NT-proCNP (0.54 (P = 0.34) and 0.61 (P = 0.12), respectively), although the power for a target AUC of 0.8 was 0.97. There was a weak correlation between PSP at days 1 to 2 and SOFA (Sepsis-related Organ Failure Assessment) score at days 1 to 2 (Spearman test, r = 0.34, P = 0.04).
Figure 1
Figure 1

Logarithm of PSP (a) and NT-proCNP (b) concentrations on days 1 and 2. Neither PSP nor NT-proCNP doses were significantly different between groups on days 1 and 2. NT-proCNP, amino terminal pro-C-type natriuretic peptide; PSP, pancreatic stone protein/regenerating protein.

Although the diagnosis criteria of sepsis, the mean delay of infection, and the incidence of sepsis might be slightly different, these results are different from those previously published [1, 3].

The major limitations are that the study was conducted at only one center and only 61 patients participated. However, the homogenous severity of our patients has to be noticed.

Many studies are devoted to finding new biomarkers to predict sepsis in the ICU. In this pilot study, neither PSP nor NT-proCNP could help in the prediction of sepsis in patients with severe trauma. Our study illustrates the complexity of validating biomarkers for sepsis prediction in an independent cohort of patients. Validation cohorts should be designed in multicenter studies to confirm every result, whether positive or negative.



area under the receiver operating characteristic curve


intensive care unit


amino terminal pro-C-type natriuretic peptide


pancreatic stone protein/regenerating protein.



The authors would like to thank Anne Portier and Catherine Jouvene-Faure for technical assistance. This work was supported by funds from the Hospices Civils de Lyon. This project is part of Advanced Diagnostics for New Therapeutic Approaches, a program dedicated to personalized medicine, coordinated by Mérieux Alliance (Lyon, France).

Authors’ Affiliations

Service de réanimation, Hôpital Edouard Herriot - Hospices Civils de Lyon, 5 place d'Arsonval, Lyon, 69003, France
EA 4174, Hémostase, Inflammation et Sepsis, Hospices Civils de Lyon - Université Claude Bernard Lyon1, 7-11 Rue Guillaume Paradin, Lyon, Cedex 08, 69372, France
Laboratoire Commun de Recherche HCL-Biomérieux, Hôpital Édouard Herriot - Hospices Civils de Lyon, 5 place d'Arsonval, Lyon, 69003, France
BioMérieux, Data and Knowledge Laboratory, 376 Chemin de l'Orme, Marcy-l'Étoile, 69280, France
Laboratoire d'immunologie cellulaire, Hôpital Édouard Herriot - Hospices Civils de Lyon, 5 place d'Arsonval, Lyon, 69003, France


  1. Keel M, Harter L, Reding T, Sun LK, Hersberger M, Seifert B, Bimmler D, Graf R: Pancreatic stone protein is highly increased during posttraumatic sepsis and activates neutrophil granulocytes. Crit Care Med 2009, 37: 1642-1648. 10.1097/CCM.0b013e31819da7d6View ArticlePubMedGoogle Scholar
  2. Llewelyn MJ, Berger M, Gregory M, Ramaiah R, Taylor AL, Curdt I, Lajaunias F, Graf R, Blincko SJ, Drage S, Cohen J: Sepsis biomarkers in unselected patients on admission to intensive or high-dependency care. Crit Care 2013, 17: R60. 10.1186/cc12588PubMed CentralView ArticlePubMedGoogle Scholar
  3. Bahrami S, Pelinka L, Khadem A, Maitzen S, Hawa G, van Griensven M, Redl H: Circulating NT-proCNP predicts sepsis in multiple-traumatized patients without traumatic brain injury. Crit Care Med 2010, 38: 161-166. 10.1097/CCM.0b013e3181b78a06View ArticlePubMedGoogle Scholar
  4. Boeck L, Graf R, Eggimann P, Pargger H, Raptis DA, Smyrnios N, Thakkar N, Siegemund M, Rakic J, Tamm M, Stolz D: Pancreatic stone protein: a marker of organ failure and outcome in ventilator-associated pneumonia. Chest 2011, 140: 925-932. 10.1378/chest.11-0018View ArticlePubMedGoogle Scholar


© BioMed Central Ltd 2013